About 8 results found for searched term "Anti-human CD3 mAb" (0.145 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M10111 | Anti-human CD3 mAb | Cytokines and Growth Factors |
| CD3 is an important marker of T cells, it is composed of five polypeptide chains: γ, δ, ε, ζ, and η. | ||
| M11388 | Anti-human CD137 mAb | Cytokines and Growth Factors |
| Biological activity: CD137(also known as 4-1BB) is an inducible cell surface receptor, a member of the tumornecrosis factor receptor (TNFR) superfamily. | ||
| M24746 | Naratuximab | Others |
| Anti-TSPAN26/CD37 Reference Antibody | ||
| Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine. | ||
| M24983 | Visilizumab | Apoptosis |
| Anti-Human CD3E Recombinant Antibody HuM291 | ||
| Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research. | ||
| M25077 | Tarlatamab | Notch |
| AMG-757 | ||
| Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research. | ||
| M25090 | Grisnilimab setaritox | Others |
| WT1-RTA | ||
| Grisnilimab setaritox (WT1-RTA), is an antihuman T cell antibody (anti-CD7) conjugating with ricin A chain (RTA). RTA is a 30-kDa peptide capable of rapidly in activating ribosomal 60S subunits. Grisnilimab setaritox is cytotoxic to CEM (T-lymphoblastic leukemia) cells in vitro with an ID50 of 53 pM. Grisnilimab setaritox also improves leukemic meningitis model in rhesus monkeys. | ||
| M25141 | Iparomlimab | PD-1/PD-L1 |
| Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research. | ||
| M25261 | Teplizumab | Others |
| MGA-031; PRV-031 | ||
| Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
